menu
    • menu
    [{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Ixaltis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Litoxetine","moa":"antidepressants (fluoxetine type)","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Ixaltis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ixaltis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ixaltis \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"EG 427","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EG 427 \/ Undisclosed"},{"orgOrder":0,"company":"Fraser Health","sponsor":"BC Support Unit | Michael Smith Foundation for Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Fraser Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraser Health \/ BC Support Unit | Michael Smith Foundation for Health Research","highestDevelopmentStatusID":"7","companyTruncated":"Fraser Health \/ BC Support Unit | Michael Smith Foundation for Health Research"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Integrative Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Mentha Piperita Oil","moa":"Smooth muscle","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Louisville \/ Integrative Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Louisville \/ Integrative Therapeutics"},{"orgOrder":0,"company":"Holostem","sponsor":"Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Human Oral Epithelium Stem Cell","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Holostem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holostem \/ Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia","highestDevelopmentStatusID":"7","companyTruncated":"Holostem \/ Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous Muscle-Derived Cell","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Innovacell Biotechnologie","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SLOVENIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Autologous Myoblast","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Medical Centre Ljubljana \/ Innovacell Biotechnologie","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Centre Ljubljana \/ Innovacell Biotechnologie"},{"orgOrder":0,"company":"Robert W. Alexander","sponsor":"Terry, Glenn C., M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Microcannula Harvest Adipose","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Robert W. Alexander","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Robert W. Alexander \/ Terry, Glenn C., M.D.","highestDevelopmentStatusID":"7","companyTruncated":"Robert W. Alexander \/ Terry, Glenn C., M.D."},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Rec 0\/0438","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SI-722","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Norwich Clinical Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"UISH001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Beech Tree Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beech Tree Labs \/ Norwich Clinical Research Associates","highestDevelopmentStatusID":"7","companyTruncated":"Beech Tree Labs \/ Norwich Clinical Research Associates"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EG 427

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            EG 427

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG110A

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor O...

                            Details : EG110A is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neurogenic Detrusor Overactivity.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : EG110A

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Holostem

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Holostem

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Human Oral Epithelium Stem Cell

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Tre...

                            Details : Autologous Human Oral Epithelium Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypospadias.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : Autologous Human Oral Epithelium Stem Cell

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Louisville

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Louisville

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mentha Piperita Oil

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Integrative Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome

                            Details : Peppermint Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cystitis, Interstitial.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : Mentha Piperita Oil

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Integrative Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fraser Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fraser Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BC Support Unit | Michael Smith Foundation for Health Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

                            Details : Tranexamic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urologic Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 18, 2020

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BC Support Unit | Michael Smith Foundation for Health Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Seikagaku

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Seikagaku

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SI-722

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK and Safety of SI-722 in IC/BPS

                            Details : SI-722 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cystitis, Interstitial.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 23, 2019

                            Lead Product(s) : SI-722

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hackensack Meridian Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hackensack Meridian Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamsulosin

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Post-operative Urinary Retention (POUR) Following Thoracic Surgery

                            Details : Tamsulosin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Retention.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2018

                            Lead Product(s) : Tamsulosin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Recordati

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Recordati

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rec 0/0438

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

                            Details : Rec 0/0438 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neurogenic Detrusor Overactivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 29, 2018

                            Lead Product(s) : Rec 0/0438

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ixaltis

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ixaltis

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Litoxetine

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incon...

                            Details : Litoxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Incontinence.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 12, 2018

                            Lead Product(s) : Litoxetine

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Li-Cor

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Li-Cor

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nerindocianine

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

                            Details : Nerindocianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Intraoperative Ureter Injury.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2017

                            Lead Product(s) : Nerindocianine

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Robert W. Alexander

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Robert W. Alexander

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Microcannula Harvest Adipose

                            Therapeutic Area : Urology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Terry, Glenn C., M.D.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

                            Details : Microcannula Harvest Adipose is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Hyperplasia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 10, 2016

                            Lead Product(s) : Microcannula Harvest Adipose

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Terry, Glenn C., M.D.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth